Literature DB >> 22353299

Use of buspirone and fluoxetine for breathing problems in Rett syndrome.

Sarenur Gökben1, Ulkü Akyol Ardıç, Gül Serdaroğlu.   

Abstract

Rett syndrome is a severe neurodevelopmental disease with a prevalence of 0.88 per 10,000 girls aged 5-18 years, and is often caused by mutations in methyl-cytosine-phosphate-guanine (CpG)-binding protein 2. Disorder of respiratory control is a prominent feature of Rett syndrome. Brainstem serotoninergic neurons are known to play an important role in the arrangement of breathing rhythm and pattern. We present a patient whose severe hyperventilation and apneic attacks resolved with the concomitant treatment of fluoxetine and buspirone. To our knowledge, we describe the first patient with Rett syndrome to receive fluoxetine for respiratory problems. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22353299     DOI: 10.1016/j.pediatrneurol.2011.12.003

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  9 in total

1.  The course of awake breathing disturbances across the lifespan in Rett syndrome.

Authors:  Daniel C Tarquinio; Wei Hou; Jeffrey L Neul; Gamze Kilic Berkmen; Jana Drummond; Elizabeth Aronoff; Jennifer Harris; Jane B Lane; Walter E Kaufmann; Kathleen J Motil; Daniel G Glaze; Steven A Skinner; Alan K Percy
Journal:  Brain Dev       Date:  2018-04-12       Impact factor: 1.961

2.  Consensus guidelines on managing Rett syndrome across the lifespan.

Authors:  Cary Fu; Dallas Armstrong; Eric Marsh; David Lieberman; Kathleen Motil; Rochelle Witt; Shannon Standridge; Paige Nues; Jane Lane; Tristen Dinkel; Monica Coenraads; Jana von Hehn; Mary Jones; Katie Hale; Bernhard Suter; Daniel Glaze; Jeffrey Neul; Alan Percy; Timothy Benke
Journal:  BMJ Paediatr Open       Date:  2020-09-13

3.  A selective 5-HT1a receptor agonist improves respiration in a mouse model of Rett syndrome.

Authors:  Erica S Levitt; Barbara J Hunnicutt; Sharon J Knopp; John T Williams; John M Bissonnette
Journal:  J Appl Physiol (1985)       Date:  2013-10-03

4.  Diurnal variation in autonomic regulation among patients with genotyped Rett syndrome.

Authors:  Michael Sean Carroll; Jan-Marino Ramirez; Debra E Weese-Mayer
Journal:  J Med Genet       Date:  2020-03-10       Impact factor: 6.318

5.  Increasing brain serotonin corrects CO2 chemosensitivity in methyl-CpG-binding protein 2 (Mecp2)-deficient mice.

Authors:  Marie A Toward; Ana P Abdala; Sharon J Knopp; Julian F R Paton; John M Bissonnette
Journal:  Exp Physiol       Date:  2012-11-23       Impact factor: 2.969

6.  Autonomic breathing abnormalities in Rett syndrome: caregiver perspectives in an international database study.

Authors:  Jessica Mackay; Jenny Downs; Kingsley Wong; Jane Heyworth; Amy Epstein; Helen Leonard
Journal:  J Neurodev Disord       Date:  2017-04-28       Impact factor: 4.025

7.  Fluoxetine increases brain MeCP2 immuno-positive cells in a female Mecp2 heterozygous mouse model of Rett syndrome through endogenous serotonin.

Authors:  Claudia Villani; Mirjana Carli; Anna Maria Castaldo; Giuseppina Sacchetti; Roberto William Invernizzi
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

8.  TrkB overexpression in mice buffers against memory deficits and depression-like behavior but not all anxiety- and stress-related symptoms induced by developmental exposure to methylmercury.

Authors:  Nina N Karpova; Jesse Saku Olavi Lindholm; Natalia Kulesskaya; Natalia Onishchenko; Marie Vahter; Dina Popova; Sandra Ceccatelli; Eero Castrén
Journal:  Front Behav Neurosci       Date:  2014-09-12       Impact factor: 3.558

9.  Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists.

Authors:  Ana P Abdala; John M Bissonnette; Adrian Newman-Tancredi
Journal:  Front Physiol       Date:  2014-05-30       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.